Form D · Biotechnology
Luminary Therapeutics, Inc.
Minneapolis, MN · CIK 0001793860
Offering snapshot reported Nov 5, 2025 · SEC filing
- Reported sold
- $1.41M Offering amount: $12.4M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 14, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 5, 2025 | Initial | $1,406,112 | No comparison | 6 | SEC filing |
| Jan 8, 2025 | Amendment | $5,222,095 | $2,842,595vs Aug 3, 2023 | 49 | SEC filing |
| Jan 8, 2025 | Initial | $5,184,500 | No comparison | 48 | SEC filing |
| Aug 3, 2023 | Amendment | $2,379,500 | $225,000vs Jan 11, 2023 | 12 | SEC filing |
| Jan 11, 2023 | Initial | $2,154,500 | No comparison | 10 | SEC filing |
| Nov 4, 2021 | Initial | $374,993 | No comparison | 3 | SEC filing |
| Feb 9, 2021 | Initial | $825,000 | No comparison | 11 | SEC filing |
| Nov 14, 2019 | Initial | $1,490,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-563183
3(a) and (b) include the conversion of approximately $581,127 in previously issued SAFEs, which will occur when the Company has sold $3,000,000 in shares of Series B-1 Preferred; 13(a) and (c) include the issuance of warrants.
Source: Form D, filed Nov 5, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Chance | Director |
| George Cox | Director |
| Jim Haymaker | Director |
| James Haymaker | Director, Promoter |
| John Hurley | Executive |
| Peter Kosa | Director |
| David Largaespada | Director, Promoter |
| Jeff Liter | Director, Executive, Promoter |
| Tracey Lodie | Director |
| Branden Moriarity | Director |
| Alexander Naydich | Director |
| Jeff Ross | Director |
| John Wells | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1200 Washington Avenue South Suite 260
Minneapolis, MN, 55415
Minneapolis, MN, 55415